In this interview, Song Yao, MD, of Roswell Park Comprehensive Cancer Center, discusses new genomic insights into triple-negative breast cancer (TNBC) in African American women. He explains the unexpected near-universal prevalence of TP53 mutations, the role of HRD-related versus aging-related signatures, and what these findings mean for treatment strategies and future clinical trials. Dr. Yao also explores potential genetic and non-genetic drivers of TNBC disparities and highlights emerging areas for further research.
Transcript
Your study found TP53 mutations in nearly all tumors. What do you think explains this very high prevalence?